This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of +17.00% and +30.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy
by Zacks Equity Research
Syndax (SNDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 237.8% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 220% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 5.77% and 36.69%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of -1.85% and 65.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
by Zacks Equity Research
NVAX and RNA are in the spotlight following Q3 results and study data, respectively.
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 13.27% and 96.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Incyte Announces Promising New Data on Oncology Candidate at ESMO
by Zacks Equity Research
INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.
Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
by Zacks Equity Research
Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host disease.
Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 50.3% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports second-quarter 2024 results.
Wall Street Analysts Believe Syndax (SNDX) Could Rally 67.11%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 67.1% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Syndax (SNDX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.
Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $20.10, marking a -0.94% move from the previous day.
Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) closed at $20.91 in the latest trading session, marking a -0.99% move from the prior day.
Syndax Pharmaceuticals (SNDX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) closed the most recent trading day at $21.94, moving +1.72% from the previous trading session.
Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $23.07, marking a -0.26% move from the previous day.
Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) closed the most recent trading day at $22.30, moving -1.24% from the previous trading session.
Syndax Pharmaceuticals (SNDX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) closed the most recent trading day at $22.58, moving +0.71% from the previous trading session.
Immunocore (IMCR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Immunocore's (IMCR) Q4 earnings call, investors will likely focus on the sales figure of Kimmtrak - its first-line treatment for metastatic uveal melanoma - and updates on its pipeline candidates.